Statins have been shown to reduce the cardiovascular mortality in both patients with elevated serum cholesterol [1] and in patients with low to normal serum cholesterol [2] . The beneficial effect of statins on cardiovascular events is correlated to the strong low-density lipoprotein (LDL) 
collagen type I and type III thereby modifying collagen fibrillogenesis and fibril packing [16] . Studies performed in decorin deficient mice have shown that in the absence of decorin, collagen fibril formation is perturbed resulting in irregular thickness of collagen fibrils and weakened mechanical strength as seen in the dermis of decorin deficient mice [17] . Bigylcan deficient mice also display a collagen related phenotype in bone development and present a disturbance of ossification [18] . From in vitro studies we know that statins cause vascular smooth muscle cells (SMCs) to synthesize proteoglycans with modified glycosaminoglycan chains that display reduced capacity to bind LDL [19] . Therefore [20] . Threshold values were chosen as described before and positive staining was expressed as percentage of total intimal area [20] . [21] . In situ zymography was performed on cryosections as described previously [22] .
Morphometric analysis and image analysis

Immunohistochemical analysis
Histochemical stainings
Collagen accumulation was detected on 3 m paraffin sections by picrosirius red staining. Qualitative analysis of collagen deposition was performed with polarized light microscopy [23] . 
Lipid accumulation in the plaques
Plasma lipid analysis
Blood was collected by heart puncture and anticoagulated with 100 mM EDTA in isotonic sodium chloride solution. Plasma was prepared via centrifugation at 850 ϫ g for 15 min. at 4ЊC and stored at Ϫ20ЊC for later analysis. Cholesterol and triglycerides were quantified using enzymatic kits from Randox (Antrim, UK). 
Human endarterectomy specimens
Results
Accumulation of collagen
The experiments were initiated using 20- 
Rosuvastatin increases accumulation of collagen binding proteoglycans
A mechanism that might increase the packing of collagen fibrils as detected in Fig. 1 is the accumulation of the collagen binding SLRPs, decorin and biglycan. As shown in Fig. 2A-C (Fig. 3) . Specifically, the amount of tightly arranged collagen was strongly increased as demonstrated by birefringence analysis (Fig. 3D-F) whereas total collagen remained unchanged. Image analysis of biglycan (Fig. 3G-I ) and decorin (Fig. 3J-L) showed increased signals of both SLRPs that were even more pronounced as at the aortic root (compared to Fig. 2 ). (Fig. 4D) . In situ zymography was used to visualize the gelatinolytic activity within the plaques on frozen sections. As depicted in Fig. 4D -F the gelatinolytic activity was considerably reduced in rosuvastatin treated animals. In accordance with the reduced collagen cleavage immunohistochemistry revealed significantly reduced expression of MMP-2, whereas MMP-9 expression levels were not altered (Fig. 4H, I ). (Fig. 5A, B) . Alternatively, we suggested that the rosuvastatin 
Decreased cleavage of collagen
Regulation of SLRP expression by rosuvastatin and polymeric collagen in vitro
; (C) quantitative image analysis. Tightly packed collagen matrix was visualized by birefringence analysis of picrosirus red staining under polarized light of (D) control; (E) rosuvastatin treated ApoE
Ϫ/Ϫ
; (F) quantitative image analysis, *P Ͻ 0.05; control, n ϭ 10, rosuvastatin, n ϭ 18. (Fig. 5D ) compared to polymeric collagen gel alone. (Fig. 7) . Furthermore, colocalization of SLRPs to the collagenous matrix was observed and the packing of collagen was increased in these samples as demonstrated by birefringence analysis of sirius red stained sections.
Fig. 3 Condensed collagen matrix and increased accumulation of SLRPs in innominate arteries of rosuvastatin treated ApoE Ϫ/Ϫ mice. Collagen and collagen matrix arrangement were analysed by picrosirius red staining and birefringence analysis, respectively. In addition decorin and biglycan were detected by immunohistochemistry in plaques of innominate arteries. (A, D, G, J) control and (B, E, H, K) rosuvastatin. (A-F) picrosirius red staining and quantitative image analysis. (D, E) picrosirius red staining viewed under polarized light. (G-I) biglycan immunostaining and quantitative image analysis. (J-L) decorin immunostaining and quantitative image analysis; control, n ϭ 4, rosuvastatin, n ϭ 11, *, P Ͻ 0.05. induced collagen-rich ECM might induce up-regulation of SLRPs in VSMC. To test this hypothesis VSMC were cultured in a three dimensional polymeric collagen gel and the expression of biglycan and decorin was compared to VSMC on plastic. Indeed both biglycan and decorin were up-regulated in VSMC cultured in a polymeric collagen gel as compared to monolayer cultures on plastic (Fig. 5C). In addition, we analysed if rosuvastatin affected the SLRP expression in collagen gels, but detected no further increase
Rosuvastatin does not affect lipid retention
Statins induce SLRPs in human atherosclerosis
Fig. 4 Rosuvastatin inhibits collagen degradation and gelatinolytic activity in atherosclerotic plaque of ApoE Ϫ/Ϫ mice. Collagen cleavage was demonstrated by staining of collagen neoepitopes originating from MMP mediated cleavage in aortic root plaques. (A) control and (B) rosuvastatin. (C) quantitative image analysis, n ϭ 8; *P Ͻ 0.05. (D) ratio between collagen neoepitopes and total collagen as determined by picrosirius red staining (Fig. 1). (E, F) MMP activity as detected by in situ zymography on cryosections in control versus rosuvastatin. (G) quantitative image analysis. (H, I) expression of MMP-2 (H) and MMP-9 (I) was analysed by immunostaining, quantitative
data from the image analysis is provided; n ϭ 8-9, *, P Ͻ 0.05. 
Discussion
The increase in collagen accumulation as reported here in response to rosuvastatin is in line with data obtained in hypercholesterolemic rabbits treated with pravastatin for 52 weeks [14] and in patients treated with atorvastatin and pravastatin [27, 28] 
